公开(公告)号：US20160195536A1

公开(公告)日：2016-07-07

申请号：US14912299

申请日：2014-08-13

申请人： Electrophoretics Limited ,  King's College Hospital NHS Foundation Trust

发明人： Yoh Zen ,  Nigel Heaton ,  Alberto Quaglia ,  David Britton ,  Malcolm Ward ,  Ian Pike ,  Vikram Mitra

IPC分类号： G01N33/574 ,  C07K2/00 ,  A61K31/506

CPC分类号： G01N33/57438 ,  A61K31/506 ,  C07K2/00 ,  G01N2440/14 ,  G01N2458/15 ,  G01N2560/00 ,  G01N2570/00

摘要： The present invention concerns materials and methods relating to pancreatic cancer and personalized medicine as applied to pancreatic cancer. Particularly, the invention relates to materials and methods for the determination of significantly modulated protein phosphorylation and/or expression as well as the activity of signalling pathways collectively providing a tumour profile that can guide selection of the most appropriate treatment regime based on the likelihood of tumour recurrence or the identity of activated drug targets in pancreatic cancer.

摘要翻译： 本发明涉及应用于胰腺癌的胰腺癌和个体化医学相关的材料和方法。 特别地，本发明涉及用于确定显着调节的蛋白质磷酸化和/或表达以及信号通路的活性的材料和方法，以及共同提供基于肿瘤可能性的指导选择最合适的治疗方案的肿瘤分布的活动 复发或胰腺癌中活化药物靶标的特征。